The largest trial ever to investigate the world’s most commonly administered drug. The HEAT Trial enrolled 700 patients across 22 Intensive Care Units in Australia and New Zealand to investigate the effect of paracetamol on critically ill patients with known or suspected infection.
The HEAT Trial
The HEAT Trial was a phase 2b randomised controlled trial investigating the safety and efficacy of intravenous paracetamol versus placebo (5% dextrose) in the treatment of fever in critically ill patients with known or suspected infection.
Co-ordinated by the Medical Research Institute of New Zealand, in collaboration with the Australian and New Zealand Clinical Trials Group, the results of the trial was published in December 2015 in the New England Journal of Medicine.
This trial used our Spinnaker software to randomise patients in 22 different locations, provided a user-friendly interface for data entry (eCRF) into our enterprise database and record events (i.e. SAE) as they happened. Spinnaker also provided management tools to assist the Chief Investigator and Project Manager. These included reporting on trial progress, interim reports generated dynamically and instantly anytime needed, and management of user access to the software.
An important component of Spinnaker is the inventory module. This module was used in the HEAT Trial to manage the study drug across all 22 locations including transfers.
To hear more about how Spinnaker helped with the HEAT Trial, get in touch.
“ At each of the 22 ICU’s involved in the study there will be at least 100 staff involved, which means a total of over 2,000 staff contributing, so our IT systems need to be very intuitive and Spiral has delivered just that. ”
Paul Young, Intensive Care Specialist, Wellington Hospital
HEAT on twitter
Read what people are saying about the HEAT Trial on Twitter
Read what people are saying about the HEAT Trial on Twitter.